Mupirocin

Ferroptosis is a newly identified iron-dependent form of death that is becoming increasingly recognized as a promising avenue for cancer therapy. N6-methyladenosine (m6A) is the most abundant reversible methylation modification in mRNA contributing to tumorigenesis. However, the crucial role of m6A modification in regulating ferroptosis during colorectal cancer (CRC) tumorigenesis remains elusive. Herein, we find that m6A modification is increased during ferroptotic cell death and correlates with the decreased m6A demethylase fat mass and obesity-associated protein (FTO) expression. Functionally, we demonstrate that suppressing FTO significantly induces CRC ferroptotic cell death, as well as enhancing CRC cell sensitivity to ferroptosis inducer (Erastin and RSL3) treatment. Mechanistically, high FTO expression increased solute carrier family 7 member 11 (SLC7A11) or glutathione peroxidase 4 (GPX4) expressions in an m6A-YTHDF2 dependent manner, thereby counteracting ferroptotic cell death stress. In addition, we identify Mupirocin as a novel inhibitor of FTO, and Mupirocin induces CRC ferroptosis and inhibits tumor growth. Clinically, the levels of FTO, SLC7A11, and GPX4, are highly correlated expression in CRC tissues. Our findings reveal that FTO protects CRC from ferroptotic cell death in promoting CRC tumorigenesis through triggering SLC7A11/GPX4 expression.

BackgroundFitness costs imposed on bacteria by antibiotic resistance mechanisms are believed to hamper their dissemination. The scale of these costs is highly variable. Some, including resistance of Staphylococcus aureus to the clinically important antibiotic mupirocin, have been reported as being cost-free, which suggests that there are few barriers preventing their global spread. However, this is not supported by surveillance data in healthy communities, which indicate that this resistance mechanism is relatively unsuccessful.ResultsEpistasis analysis on two collections of MRSA provides an explanation for this discord, where the mupirocin resistance-conferring mutation of the ileS gene appears to affect the levels of toxins produced by S. aureus when combined with specific polymorphisms at other loci. Proteomic analysis demonstrates that the activity of the secretory apparatus of the PSM family of toxins is affected by mupirocin resistance. As an energetically costly activity, this reduction in toxicity masks the fitness costs associated with this resistance mutation, a cost that becomes apparent when toxin production becomes necessary. This hidden fitness cost provides a likely explanation for why this mupirocin-resistance mechanism is not more prevalent, given the widespread use of this antibiotic.ConclusionsWith dwindling pools of antibiotics available for use, information on the fitness consequences of the acquisition of resistance may need to be considered when designing antibiotic prescribing policies. However, this study suggests there are levels of depth that we do not understand, and that holistic, surveillance and functional genomics approaches are required to gain this crucial information.

The effectiveness of essential oils (EOs), fluconazole (FLU) and mupirocin (MUP) used alone or in combination against mono-species and mixed Candida albicans/Staphylococcus aureus biofilms was examined. An experimentally established dual-species biofilm model, verified by fluorescence microscopy and viable cell counting, was used. Selected commercial EOs were tested: geranium, citronella and clove oils, which have been chemically characterized and found to differ in the content of the main components (qualitative and quantitative). As expected, C. albicans and S. aureus biofilms were less susceptible to fluconazole and mupirocin action, respectively, compared to the planktonic counterparts. However, the drug effectiveness in combination with the EOs was significantly improved, giving enhancement of biofilm eradication than caused by the antibiotics alone. Moreover, dual-species biofilm formation was limited by sub-MIC of EOs, and preformed mixed biofilm was eliminated more efficiently by combined action of drugs and EOs.

IntroductionThis study aims to fabricate dual drug-loaded nanofibrous films made from polyvinyl alcohol (PVA) and chitosan, incorporating cefadroxil and mupirocin to meet the critical needs of burn wound care.MethodsElectrospinning was utilized to fabricate cefadroxil- and mupirocin-loaded polyvinyl alcohol PVA/Chitosan nanofibers. Characterization of structural and morphological properties of these nanofibers was done through Fourier Transform IR Spectroscopy, Scanning Electron Microscopy, Thermal analysis by TGA, and XRD spectroscopy. The kinetic profiles of the drug release mechanisms were considered to determine the release of cefadroxil and mupirocin. Antibacterial activity was determined against the bacteria Staphylococcus aureus and Pseudomonas aeruginosa, while the wound healing efficacy was tested in a rabbit model using full-thickness wounds.ResultsSEM analysis demonstrated the formation of uniform and smooth nanofibers possessing a well-defined morphology. FTIR spectroscopy confirmed the successful incorporation of cefadroxil and mupirocin into the PVA/Chitosan matrix. TGA analysis indicated the thermal stability of the nanofibers, while XRD results suggested that the drugs were either molecularly dispersed or in an amorphous state within the biopolymeric blend. Drug release studies showed distinct profiles, with an initial burst release followed by sustained drug release. Over 80% of mupirocin was released within the first 2 hours, while cefadroxil exhibited a cumulative release exceeding 60%. Antibacterial assays showed significant inhibition zones, with the largest being 20 mm against Staphylococcus aureus. In vivo studies utilizing a full-thickness rabbit wound model revealed that the drug-loaded nanofibers accelerated wound contraction, achieving approximately 90% closure by day 17, compared to less than 70% for the control.DiscussionThe dual drug-loaded PVA/Chitosan nanofiber films demonstrated excellent antibacterial efficacy and improved wound healing, indicating their therapeutic potential for burn wound management. The combination of cefadroxil and mupirocin within the nanofiber matrix enabled rapid initial drug release followed by sustained delivery, contributing to effective infection control and tissue regeneration.ConclusionThe study demonstrates that cefadroxil-mupirocin nanofiber films provide superior antibacterial activity and faster wound healing rates, highlighting their potential in advanced burn wound management.